Postprandial hyperglycemia on vascular endothelial function: Mechanisms and consequences

Nutrition Research

Volumn 32, Issue 10, 2012, Pages 727-740

  Mah, Eunice ^a   Bruno, Richard S ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Asymmetric dimethylarginine; Cardiovascular disease; Nitric oxide; Oxidative stress; Postprandial hyperglycemia; Vascular endothelial function

Indexed keywords

ARGINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; ENDOTHELIAL DYSFUNCTION; ENZYME DEGRADATION; ENZYME INHIBITION; FUNCTIONAL ASSESSMENT; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VEIN OCCLUSION PLETHYSMOGRAPHY;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HOMEOSTASIS; HUMANS; HYPERGLYCEMIA; NITRIC OXIDE; OXIDATIVE STRESS; POSTPRANDIAL PERIOD;

EID: 84869083239     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.08.002     Document Type: Review

References (134)

1. Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States 2011. U.S. Department of Health and Human Services 2011, 1-12.
2. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161:397-405. DECODE Study Group.
3. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
4. Sekikawa A., Tominaga M., Takahashi K., Eguchi H., Igarashi M., Ohnuma H., et al. Prevalence of diabetes and impaired glucose tolerance in Funagata area, Japan. Diabetes Care 1993, 16:570-574.
5. O'Keefe J.H., Gheewala N.M., O'Keefe J.O. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008, 51:249-255.
6. Abdul-Ghani M.A., Tripathy D., DeFronzo R.A. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006, 29:1130-1139.
7. Hanefeld M., Koehler C., Fuecker K., Henkel E., Schaper F., Temelkova-Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 2003, 26:868-874.
8. Festa A., D'Agostino R., Hanley A.J., Karter A.J., Saad M.F., Haffner S.M. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 2004, 53:1549-1555.
9. Miyazaki Y., Akasaka H., Ohnishi H., Saitoh S., DeFronzo R.A., Shimamoto K. Differences in insulin action and secretion, plasma lipids and blood pressure levels between impaired fasting glucose and impaired glucose tolerance in Japanese subjects. Hypertens Res 2008, 31:1357-1363.
10. Novoa F.J., Boronat M., Saavedra P., Diaz-Cremades J.M., Varillas V.F., La Roche F., et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diabetes Care 2005, 28:2388-2393.
11. Davies M.J., Raymond N.T., Day J.L., Hales C.N., Burden A.C. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 2000, 17:433-440.
12. Heldgaard P.E., Olivarius Nde F., Hindsberger C., Henriksen J.E. Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease. Diabet Med 2004, 21:363-370.
13. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
14. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
15. Raz I., Wilson P.W., Strojek K., Kowalska I., Bozikov V., Gitt A.K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32:381-386.
16. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
17. Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009, 32(Suppl. 2):S314-S321.
18. Su Y., Liu X.M., Sun Y.M., Jin H.B., Fu R., Wang Y.Y., et al. The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int J Clin Pract 2008, 62:877-882.
19. Wilkinson I.B., Webb D.J. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 2001, 52:631-646.
20. Thijssen D.H., Black M.A., Pyke K.E., Padilla J., Atkinson G., Harris R.A., et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011, 300:H2-H12.
21. Fichtlscherer S., Breuer S., Zeiher A.M. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. Circulation 2004, 110:1926-1932.
22. Lind L., Sarabi M., Millgard J. The effect of smoking on endothelial vasodilatory function evaluated by local infusion of metacholine in the forearm is dependent on the duration of smoking. Nicotine Tob Res 2003, 5:125-130.
23. Irace C., Ceravolo R., Notarangelo L., Crescenzo A., Ventura G., Tamburrini O., et al. Comparison of endothelial function evaluated by strain gauge plethysmography and brachial artery ultrasound. Atherosclerosis 2001, 158:53-59.
24. Pasimeni G., Ribaudo M.C., Capoccia D., Rossi F., Bertone C., Leonetti F., et al. Non-invasive evaluation of endothelial dysfunction in uncomplicated obesity: relationship with insulin resistance. Microvasc Res 2006, 71:115-120.
25. Higashi Y., Sasaki S., Nakagawa K., Matsuura H., Kajiyama G., Oshima T. Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 2001, 37:863-870.
26. Perticone F., Ceravolo R., Pujia A., Ventura G., Iacopino S., Scozzafava A., et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104:191-196.
27. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
28. Sorensen K.E., Celermajer D.S., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Thomas O., et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995, 74:247-253.
29. Inaba Y., Chen J.A., Bergmann S.R. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 2010, 26:631-640.
30. Yeboah J., Folsom A.R., Burke G.L., Johnson C., Polak J.F., Post W., et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009, 120:502-509.
31. Woo K.S., Chook P., Yu C.W., Sung R.Y., Qiao M., Leung S.S., et al. Effects of diet and exercise on obesity-related vascular dysfunction in children. Circulation 2004, 109:1981-1986.
32. Johnson H.M., Gossett L.K., Piper M.E., Aeschlimann S.E., Korcarz C.E., Baker T.B., et al. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2010, 55:1988-1995.
33. Kawano H., Motoyama T., Hirashima O., Hirai N., Miyao Y., Sakamoto T., et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34:146-154.
34. Mah E., Noh S.K., Ballard K.D., Matos M.E., Volek J.S., Bruno R.S. Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine. J Nutr 2011, 141:1961-1968.
35. Watanabe K., Oba K., Suzuki T., Ouchi M., Suzuki K., Futami-Suda S., et al. Oral glucose loading attenuates endothelial function in normal individual. Eur J Clin Invest 2011, 41:465-473.
36. Akbari C.M., Saouaf R., Barnhill D.F., Newman P.A., LoGerfo F.W., Veves A. Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. J Vasc Surg 1998, 28:687-694.
37. Ceriello A., Taboga C., Tonutti L., Quagliaro L., Piconi L., Bais B., et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002, 106:1211-1218.
38. Chittari M.V., McTernan P., Bawazeer N., Constantinides K., Ciotola M., O'Hare J.P., et al. Impact of acute hyperglycaemia on endothelial function and retinal vascular reactivity in patients with type 2 diabetes. Diabet Med 2011, 28:450-454.
39. Ihlemann N., Rask-Madsen C., Perner A., Dominguez H., Hermann T., Kober L., et al. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am J Physiol Heart Circ Physiol 2003, 285:H875-H882.
40. Schmoelzer I., Wascher T.C. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc Diabetol 2006, 5:9.
41. Title L.M., Cummings P.M., Giddens K., Nassar B.A. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000, 36:2185-2191.
42. Major-Pedersen A., Ihlemann N., Hermann T.S., Christiansen B., Dominguez H., Kveiborg B., et al. Effects of oral glucose load on endothelial function and on insulin and glucose fluctuations in healthy individuals. Exp Diabetes Res 2008, 2008:672021.
43. Siafarikas A., Watts K., Beye P., Jones T.W., Davis E.A., Green D.J. Lack of effect of oral glucose loading on conduit vessel endothelial function in healthy subjects. Clin Sci (Lond) 2004, 107:191-196.
44. Xiang G.D., Sun H.L., Zhao L.S., Hou J., Yue L., Xu L. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance. Clin Endocrinol (Oxf) 2008, 68:716-723.
45. Williams S.B., Goldfine A.B., Timimi F.K., Ting H.H., Roddy M.A., Simonson D.C., et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998, 97:1695-1701.
46. Muniyappa R., Quon M.J. Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 2007, 10:523-530.
47. Hermann T.S., Ihlemann N., Dominguez H., Rask-Madsen C., Kober L., Torp-Pedersen C. Prolonged local forearm hyperinsulinemia induces sustained enhancement of nitric oxide-dependent vasodilation in healthy subjects. Endothelium 2004, 11:231-239.
48. Reed A.S., Charkoudian N., Vella A., Shah P., Rizza R.A., Joyner M.J. Forearm vascular control during acute hyperglycemia in healthy humans. Am J Physiol Endocrinol Metab 2004, 286:E472-E480.
49. Coffman T.M. Under pressure: the search for the essential mechanisms of hypertension. Nat Med 2011, 17:1402-1409.
50. Michiels C. Endothelial cell functions. J Cell Physiol 2003, 196:430-443.
51. Green D.J., Jones H., Thijssen D., Cable N.T., Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter?. Hypertension 2011, 57:363-369.
52. Khrenov A.V., Ananyeva N.M., Griffin J.H., Saenko E.L. Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 2002, 12:317-324.
53. Gresele P., Marzotti S., Guglielmini G., Momi S., Giannini S., Minuz P., et al. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 2010, 33:1262-1268.
54. Stratmann B., Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005, 2:16-23.
55. Vaidyula V.R., Boden G., Rao A.K. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 2006, 17:577-585.
56. Davis C., Fischer J., Ley K., Sarembock I.J. The role of inflammation in vascular injury and repair. J Thromb Haemost 2003, 1:1699-1709.
57. Nakamura N., Ueno Y., Tsuchiyama Y., Koike Y., Gohda M., Satani O. Isolated post-challenge hyperglycemia in patients with normal fasting glucose concentration exaggerates neointimal hyperplasia after coronary stent implantation. Circ J 2003, 67:61-67.
58. Wang L., Zhu L.H., Jiang H., Tang Q.Z., Yan L., Wang D., et al. Grape seed proanthocyanidins attenuate vascular smooth muscle cell proliferation via blocking phosphatidylinositol 3-kinase-dependent signaling pathways. J Cell Physiol 2010, 223:713-726.
59. Sun J., Xu Y., Dai Z., Sun Y. Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Mol Cell Endocrinol 2009, 313:64-69.
60. Gadeau A.P., Campan M., Millet D., Candresse T., Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 1993, 13:120-125.
61. Hu T., Luan R., Zhang H., Lau W.B., Wang Q., Zhang Y., et al. Hydrogen peroxide enhances osteopontin expression and matrix metalloproteinase activity in aortic vascular smooth muscle cells. Clin Exp Pharmacol Physiol 2009, 36:626-630.
62. Kato T., Inoue T., Morooka T., Yoshimoto N., Node K. Short-term passive smoking causes endothelial dysfunction via oxidative stress in nonsmokers. Can J Physiol Pharmacol 2006, 84:523-529.
63. Keaney J.F., Larson M.G., Vasan R.S., Wilson P.W., Lipinska I., Corey D., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003, 23:434-439.
64. Stephens J.W., Khanolkar M.P., Bain S.C. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 2009, 202:321-329.
65. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
66. Zheng F., Lu W., Jia C., Li H., Wang Z., Jia W. Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation. Endocrine 2010, 37:201-208.
67. Cadenas E., Davies K.J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000, 29:222-230.
68. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
69. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
70. Piconi L., Quagliaro L., Assaloni R., Da Ros R., Maier A., Zuodar G., et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 2006, 22:198-203.
71. Huang T.T., Carlson E.J., Kozy H.M., Mantha S., Goodman S.I., Ursell P.C., et al. Genetic modification of prenatal lethality and dilated cardiomyopathy in Mn superoxide dismutase mutant mice. Free Radic Biol Med 2001, 31:1101-1110.
72. Shimizu T., Nojiri H., Kawakami S., Uchiyama S., Shirasawa T. Model mice for tissue-specific deletion of the manganese superoxide dismutase gene. Geriatr Gerontol Int 2010, 10(Suppl. 1):S70-S79.
73. Thomas G.P., Stephen P.M. Protective action of clonidine against the arrhythmogenic and lethal effects of ouabain in guinea-pigs. Br J Pharmacol 1991, 104:995-999.
74. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
75. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009, 94:3171-3182.
76. Konukoglu D., Firtina S., Serin O. The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. Metabolism 2008, 57:110-115.
77. 2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 2006, 12:RA5-RA16.
78. Festa A., D'Agostino R., Tracy R.P., Haffner S.M. C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Diabet Med 2002, 19:939-943.
79. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004, 53:701-710.
80. Derosa G., D'Angelo A., Salvadeo S.A., Ferrari I., Fogari E., Gravina A., et al. Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. Horm Metab Res 2010, 42:8-13.
81. Piconi L., Quagliaro L., Da Ros R., Assaloni R., Giugliano D., Esposito K., et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004, 2:1453-1459.
82. Pietschmann P., Gollob E., Brosch S., Hahn P., Kudlacek S., Willheim M., et al. The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol 2003, 38:1119-1127.
83. Ungvari Z., Kaley G., de Cabo R., Sonntag W.E., Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 2010, 65:1028-1041.
84. Brandes R.P., Weissmann N., Schroder K. NADPH oxidases in cardiovascular disease. Free Radic Biol Med 2010, 49:687-706.
85. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313.
86. Ago T., Kitazono T., Ooboshi H., Iyama T., Han Y.H., Takada J., et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004, 109:227-233.
87. Williams C.R., Lu X., Sutliff R.L., Hart C.M. Rosiglitazone attenuates NF-kappaB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells. Am J Physiol Cell Physiol 2012, 303:C213-C223.
88. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003, 52:2795-2804.
89. Gopalakrishna R., Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med 2000, 28:1349-1361.
90. Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., Zuodar G., et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005, 183:259-267.
91. Beckman J.A., Goldfine A.B., Gordon M.B., Garrett L.A., Creager M.A. Inhibition of protein kinase C beta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002, 90:107-111.
92. Beckman J.A., Goldfine A.B., Goldin A., Prsic A., Kim S., Creager M.A. Inhibition of protein kinase C beta does not improve endothelial function in type 2 diabetes. J Clin Endocrinol Metab 2010, 95:3783-3787.
93. Jones W.K., Brown M., Wilhide M., He S., Ren X. NF-kappaB in cardiovascular disease: diverse and specific effects of a "general" transcription factor?. Cardiovasc Toxicol 2005, 5:183-202.
94. Kempe S., Kestler H., Lasar A., Wirth T. NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res 2005, 33:5308-5319.
95. 3K/Akt/eNOS pathway. Cell Signal 2006, 18:391-399.
96. Mariappan N., Elks C.M., Sriramula S., Guggilam A., Liu Z., Borkhsenious O., et al. NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res 2010, 85:473-483.
97. Aljada A., Friedman J., Ghanim H., Mohanty P., Hofmeyer D., Chaudhuri A., et al. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism 2006, 55:1177-1185.
98. Chu C.S., Lee K.T., Cheng K.H., Lee M.Y., Kuo H.F., Lin T.H., et al. Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes. Cardiovasc Diabetol 2012, 11:21.
99. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001, 357:593-615.
100. Forstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 2006, 387:1521-1533.
101. Zhu M., Chen J., Tan Z., Wang J. Propofol protects against high glucose-induced endothelial dysfunction in human umbilical vein endothelial cells. Anesth Analg 2012, 114:303-309.
102. Cai S., Khoo J., Mussa S., Alp N.J., Channon K.M. Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 2005, 48:1933-1940.
103. Mayer B. Nitric Oxide 2000, Springer-Verlag, Berlin.
104. Daff S. NO synthase: structures and mechanisms. Nitric Oxide 2010, 23:1-11.
105. Kuzkaya N., Weissmann N., Harrison D.G., Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003, 278:22546-22554.
106. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103:1282-1288.
107. Milstien S., Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999, 263:681-684.
108. Crabtree M.J., Smith C.L., Lam G., Goligorsky M.S., Gross S.S. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol Heart Circ Physiol 2008, 294:H1530-H1540.
109. Vasquez-Vivar J., Martasek P., Whitsett J., Joseph J., Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem J 2002, 362:733-739.
110. Wu G., Morris S.M. Arginine metabolism: nitric oxide and beyond. Biochem J 1998, 336(Pt 1):1-17.
111. Ryoo S., Lemmon C.A., Soucy K.G., Gupta G., White A.R., Nyhan D., et al. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 2006, 99:951-960.
112. Chang C.I., Zoghi B., Liao J.C., Kuo L. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide production. J Immunol 2000, 165:2134-2141.
113. 2 impairs endothelium-dependent nitric oxide-mediated dilation of coronary arterioles. Arterioscler Thromb Vasc Biol 2006, 26:2035-2042.
114. Wang W., Hein T.W., Zhang C., Zawieja D.C., Liao J.C., Kuo L. Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I. Microcirculation 2011, 18:36-45.
115. Romero M.J., Platt D.H., Tawfik H.E., Labazi M., El-Remessy A.B., Bartoli M., et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008, 102:95-102.
116. Romero M.J., Iddings J.A., Platt D.H., Ali M.I., Cederbaum S.D., Stepp D.W., et al. Diabetes-induced vascular dysfunction involves arginase I. Am J Physiol Heart Circ Physiol 2012, 302:H159-H166.
117. Shearer J.D., Richards J.R., Mills C.D., Caldwell M.D. Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Am J Physiol 1997, 272:E181-E190.
118. Pope A.J., Karuppiah K., Cardounel A.J. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res 2009, 60:461-465.
119. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
120. G-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases?. Am J Physiol 1995, 269:C750-C756.
121. Palm F., Onozato M.L., Luo Z., Wilcox C.S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007, 293:H3227-H3245.
122. De Gennaro Colonna V., Bianchi M., Pascale V., Ferrario P., Morelli F., Pascale W., et al. Asymmetric del cardiovascular risk molecule. Med Sci Monit 2009, 15:RA91-RA101.
123. Boger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003, 59:824-833.
124. Boger R.H. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005, 10(Suppl. 1):S19-S25.
125. Lu C.W., Guo Z., Feng M., Wu Z.Z., He Z.M., Xiong Y. Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells. Atherosclerosis 2010, 209:66-73.
126. Frombaum M., Therond P., Djelidi R., Beaudeux J.L., Bonnefont-Rousselot D., Borderie D. Piceatannol is more effective than resveratrol in restoring endothelial cell dimethylarginine dimethylaminohydrolase expression and activity after high-glucose oxidative stress. Free Radic Res 2011, 45:293-302.
127. Mah E, Noh SK, Ballard KD, Park HJ, Volek JS, Bruno RS. Supplementation of a γ-tocopherol-rich mixture of tocopherols in healthy men protects against vascular endothelial dysfunction induced by postprandial hyperglycemia. J Nutr Biochem [Epub ahead of press; ]. http://dx.doi.org/10.1016/j.jnutbio.2012.04.015.
128. American Diabetes Association Standards of medical care in diabetes--2012. Diabetes Care 2012, 35(Suppl. 1):S11-S63.
129. Unwin N., Shaw J., Zimmet P., Alberti K.G. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002, 19:708-723.
130. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330:1029-1035.
131. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150-1155.
132. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
133. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.
134. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:154-160.